CompletedPhase 3NCT00801281

First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.

Studying Indolent B-cell non-Hodgkin lymphoma

Last synced from ClinicalTrials.gov May 5, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Polish Lymphoma Research Group
Principal Investigator: Jan A Walewski, Prof.
Vice-president of PLRG
Intervention: Rituximab(drug)
Enrollment: 250 enrolled
Eligibility: 18 years · All sexes
Timeline: 2007 – 2017

Study locations (12)

Podkarpacki Oncology Centre, Brzozów, Poland
Voivodeship Hospital, Oncology Ward, Elblag, Poland
Academic Clinical Centre, Hospital of Medical Academy, Clinic of Haematology and Transplantology, Gdansk, Poland
Silesian Medical University, Chair and Clinic of Haematology and Bone Marrow Transplantation, Katowice, Poland
Collegium Medicum Jagiellonian University, Clinic of Haematology, Krakow, Poland
Regional Oncology Centre, Ward of Proliferative Diseases, Lodz, Poland
Oncology Centre of Lublin Region, Lublin, Poland
Central Clinical Hospital, Ministry of Internal Matters and Administration; Clinic of Oncology, Haematology and Internal Diseases, Warsaw, Poland
Institute of Haematology and Transfusiology, Warsaw, Poland
M.Sklodowska-Curie Institute - Oncology Centre, Warsaw, Poland
Medical Academy in Wrocław; Chair and Clinic of Haematology, Blood Neoplasm and Bone Marrow Transplantation, Wroclaw, Poland
SP ZOZ Silesian Centre of Cellular Transplantation, Wroclaw, Poland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00801281 on ClinicalTrials.gov

Other trials for Indolent B-cell non-Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Indolent B-cell non-Hodgkin lymphoma →

← Back to all trials